Riga Cellbox LabsDeveloping small human organs out of the body has secured $ 3.3 million for non-duel funds to accelerate the development of its dynamic organ-on-a-chip technology.
Part of this fund comes from state assistance under the important European interest (IPEII) in the healthcare sector, known as “Tech 4 Q”, which strengthens EU industry elasticity and strengthens the single market.
The company mentioned in a public statement: “On-chip systems on personalized bowel unlocking new values for pharma, nutrition and effective food industry, to properly predict the unique reactions of drugs, food and probiotics. “
Established in 2020 by Aarts-Bols, Gatis Mozoevskis and Roberts Rimia, Cellbox labs specialized in creating organ-on-chip system; Micro Engineers setups that separate endothelial and epithelial layers with an accessible membrane. It allows modeling of organs such as kidneys, intestines, lungs, blood-brain barriers and pancreas, using non-exploiting materials favorable for drug discoveries.
The platform supports controlled gas terms, mass produced for reproductiveness and is featured in an automatic system that reduces manual work when enables scalble Thrup on 8 to 24 chips.
The fund will be channel on four main initiatives.
- First, in collaboration with Altis Biostes, the Cellbox labs will scale an automated, primary cell-based gut-on-chip model for pharmaceutical thrips, will move on to personalized models by using the persuasive Pluripotent Stem Cell (IPSC) and patient-based microboyota.
- Second, the company produces live data without additional hardware and each organ-on-chip asce will integrate oxygen and pH sensors directly. It matches the change of art towards a more prosperous datasate for the invention of AI-driven drugs.
- Third, the party will benchmark the biosima performance by examining the GLP-1 generic on the pancreatic islet organic-on-chip systems, comparing the results with a fixed culture and animal model to improve the physiological relevance of the biosimala test.
- Fourth, as well as Esclabs and MPSLABS, Cellbox labs will develop high-union digital twin models of its intro systems, integrating Vitro-in Vivo translation (IVIVE) with their physiological-based human models. Its aim is to strengthen the prediction of organ-on-chip platforms for human outcomes.
This strategic roadmap is integrated with the need for animal testing for specific drugs and the NIH’s computer modeling, AI and funding research to include organ-on-chip technology, such as the NIH order, such as the regulatory development of the FDA plan.
Startup was raised before 2024 pre-bins 935k dollars Latbian Angels, ASP Asset Management AIFP and Private Investor Ansis Sprdjans led by Latvian Building VC.
With its latest capital injection, the purpose of the Cellbox labs is predictable, data-rich and not accelerated on personalized drug test platforms-not rely on-to accelerate its push-on-her test.
[publish_date
